Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

German Hepatitis C-Registry (DHC-R)

Trial Profile

German Hepatitis C-Registry (DHC-R)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boceprevir (Primary) ; Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms DHC-R
  • Most Recent Events

    • 24 Jun 2023 Results (n=2727, data cut off Nov17,2021) assessing the real-world effect of glecaprevir/pibrentasvir(G/P) on quality of life (QoL) 1-year posttreatment presented at the European Association for the Study of the Liver Congress 2023
    • 01 Oct 2021 Results (n=14357) of an analysis assessing data for all patients who completed a screening visit within any one of the registry phases (phase 1-7) which were based on inclusion of specific HCV therapies in the registry published in the Journal of Viral Hepatitis
    • 01 Jul 2021 Results (n=187) assessing real-world effectiveness and safety of 8 weeks of glecaprevir/pibrentasvir in compensated cirrhosis patients and effectiveness in GT3- versus non-GT3-infected patients in the German Hepatitis C-Registry (DHC-R), published in the Liver International.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top